IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Down 24.0% in December

IceCure Medical Ltd. (NASDAQ:ICCM) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 885,740 shares, a decline of 24.0% from the November 30th total of 1,164,983 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily volume of 349,862 shares, the short-interest ratio is currently 2.5 days. Based on an average daily volume of 349,862 shares, the short-interest ratio is currently 2.5 days. Approximately 1.3% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a report on Wednesday, October 8th. HC Wainwright upped their price objective on IceCure Medical from $2.00 to $2.50 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $2.64.

IceCure Medical Stock Down 6.0%

ICCM traded down $0.04 on Tuesday, reaching $0.61. The company had a trading volume of 812,982 shares, compared to its average volume of 362,372. IceCure Medical has a 1 year low of $0.59 and a 1 year high of $1.66. The stock has a market capitalization of $41.91 million, a PE ratio of -2.35 and a beta of 0.28. The stock has a 50-day moving average price of $0.70 and a 200-day moving average price of $0.88.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). IceCure Medical had a negative return on equity of 243.68% and a negative net margin of 513.95%.The firm had revenue of $0.85 million for the quarter, compared to analysts’ expectations of $0.63 million. As a group, analysts expect that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.